Audit: QRS - Resistance Training for Health & Longevity
Audit conducted on 01/09/2026 06:18 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol cells trace to ER lines 376–384; time-to-effect to ER line 431; benefits/risks to the ER tier headings; all 10 monitoring rows and the cadence to ER lines 459–472; at-a-glance to ER lines 501–503. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | No ER section is empty; cautious qualifiers such as “in predisposed individuals” (risks_low) are carried over from ER line 293. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Gate severities preserved: fluoroquinolones remain an absolute contraindication (ER line 323); “Caution”/”Monitor”/”Beneficial addition” markers match ER lines 321–345 one-for-one. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | All 12 caution_items and all 7 stop_items originate in the ER Key Interactions & Contraindications section; nothing is drawn from Benefit- or Risk-Modifying Factors. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, citations, NCT identifiers or brand names appear anywhere in the QRS; the Attia / LIFTMOR / Schoenfeld / Huberman attributions of ER lines 380–384 are correctly stripped. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Detached, evidence-first register throughout, matching the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets (10 hard sets, 85% 1RM, 40 kg grip) alongside plain framing of what is and is not established. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Gates state conditions and thresholds; no instructions are issued to a reader. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Contraindication items are stated as conditions (“until treated”, “until resolved”), mirroring ER lines 349–354. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrences of “recommend”, “advise”, or “should” in the QRS voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are confined to the decision gates and monitoring table where they are the marker names themselves. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every list item is a clipped noun phrase; no item carries a subordinate explanatory clause. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”, “your”, “we”, or “our”. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Optimal-range targets (HbA1c 4.8–5.4%, hs-CRP below 1.0 mg/L, insulin 2–5 µIU/mL) rather than conventional laboratory cut-offs. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Two to three whole-body sessions weekly plus scan-based monitoring assumes a committed reader. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Bone-density and appendicular lean-mass scans, dynamometry and cystatin C are not general-population measures. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance names the observational-only basis of the longevity claim, and risks are bounded to unsupervised maximal lifting, exactly as the ER frames it. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the header uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “blood sugar” in at_a_glance and time_3_label is the ER’s own wording (ER lines 133, 431) and is required in the At-A-Glance by item 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All verified verbatim at lines 446, 495, 539, 569, 600, 664, 693, 697–699, 851 and the four tier labels in each of the Benefits and Risks cards. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Every template variable is present; marker_#* is instantiated 10 times and qualitative_item# 6 times. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three <span website="..."> spans and the entire CSS/head/footer block are byte-identical to the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section mapped into the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels (“Core weekly structure”, “Weekly volume target”, “Approach A — strength-first heavy loading”) are verbatim; gate labels retain the ER head term with parentheticals trimmed as items 9.4/9.5 require. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Monitoring row names and qualitative items are verbatim from the ER table and list; time labels are lifted from the ER’s own “Time to effect” wording. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji present; the ER’s 🟩/🟥/🟨/⚠️ markers are all stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every item is reduced to a clipped phrase (gate items to label plus severity plus a four-to-six-word consequence; monitoring “Why” cells to five or six words), and no second page structure is introduced. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14; the only preceding line is the doctype. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:04" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: resistance_training_2026-0901-0353_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the prompt version. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0901-0554. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the on-disk filename exactly. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys, including the tooling-added git_user and git_issue. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Resistance Training for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417 matches ER frontmatter canonical_topic with the ampersand encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/01/2026”, correct for qrs_creation_date 2026-0901-0554. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header is title plus the template subline only; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER lines 501–503: what is established in trials, what rests on observation, and the bounded harm profile. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Trial-established outcome list → ER line 501; “observing people who already train” → ER line 501; sprains/strains/dropped weights from unsupervised maximal lifting → ER line 503. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “blood sugar handling”, “low mood”, “arthritic joint pain”, “Living longer” are used in place of glycaemic control, depressive symptoms, osteoarthritis and mortality. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No named study, year, or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No SMD, relative risk, mmHg or percentage figure appears. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Six items from the “Populations who should avoid Resistance Training” list (ER lines 349–354) plus the fluoroquinolone absolute contraindication (ER line 323). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All seven ER-declared contraindications are present; none is omitted or added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Seven <li> elements inside the stop_items span (lines 572–595). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s explanatory glosses (“heart attack”, “chest pain at rest from restricted blood flow to the heart”, “inherited connective-tissue disorders that weaken artery walls”) are all stripped; no dash-led trailing clause remains. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “New York Heart Association Class IV”, “within 90 days”, “at or above 180/110 mmHg”, “above 4.5 cm”, “above five times the upper limit” and the one-month fluoroquinolone window are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER identifies such populations and the section is correspondingly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All twelve items map one-for-one onto ER lines 321–345. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Thirteen ER interaction bullets minus the fluoroquinolone bullet (carried into Contraindications) equals the twelve items present. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Twelve <li> elements inside the caution_items span (lines 603–654). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item reduces to label, severity marker and a short consequence; the ER’s “Supplements with additive effects — “ and “Other interventions — “ em-dash prefixes are stripped, and no mitigation prose is carried over. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named drug examples are retained for every drug class, trimmed to two per class; the vitamin C 1 g/day, vitamin E 400 IU/day, creatine 3–5 g, protein 1.62 g/kg/day and caffeine 200 mg thresholds are all preserved. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies twelve such interactions and the section is correspondingly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Cells trace to ER Therapeutic Protocol lines 376–384. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Core weekly structure, weekly volume target, and the load-strategy choice — the three variables that determine what a session actually looks like. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine variables carry ER-derived content; the volume sub-line reproduces the 0.37%-per-set figure and the ~10-set plateau from ER line 378. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Strength (with muscle size in the sub-line), bone density, and blood pressure plus blood sugar — the full content of ER line 431. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Order follows the ER Expected Benefits High tier: muscular strength and physical function, then bone mineral density, then resting blood pressure and glycaemic control. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies at least three time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | 2–4 weeks, 6–12 months and 8–12 weeks all match ER line 431; the site-specificity sub-line matches ER line 163. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All fourteen entries correspond to the ER’s fourteen benefit sub-headings. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at lines 541–562. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Semicolon-separated bare outcome names; no SMD, confidence interval, or magnitude prose from the ER is carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits variable. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers are populated in the ER, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven entries correspond to the ER’s seven risk sub-headings. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at lines 666–687. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The 970,801-injury, 320/250 mmHg and 14.8% figures from the ER are all correctly omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks variable. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers are populated in the ER, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows and cadence trace to ER Monitoring Protocol & Defining Success, lines 459–472. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten ER biomarker-table rows are present and in ER order, with optimal ranges preserved verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 842: reproduces the 4-weekly, monthly, 3-month, 6–12-month and 12–24-month intervals and the conditional creatine kinase draw from ER line 459. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Taken from the “Qualitative markers to track alongside the numbers” list, ER lines 476–481. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are present, verbatim and in ER order. |
Issues 01/09/2026 06:18
Pass rate 100.00%. No issues found.
Issues 01/09/2026 06:10
- 4.5 — Exceeds the one-A4-page budget: Laid out against the print CSS (A4, 12 mm padding, ~527 pt × 774 pt usable), the QRS blocks total roughly 1,760 pt, about 2.3 pages; the Key Interactions gate (lines 604–661, ~34 wrapped lines), the 10-row Monitoring table (lines 700–845), and the Protocol panel (lines 445–535) are the dominant contributors and were not condensed to fit.
Fixes 01/09/2026 06:10
- 4.5 — Page budget condensation: Condensed the highest-volume blocks without dropping any mandated item — the Key Interactions gate from 34 to 27 wrapped lines (drug-example lists trimmed per item 9.5, consequence clauses tightened, e.g. “Additive muscle injury risk with heavy eccentric loading” → “Additive muscle injury risk”), the Contraindications gate from 20 to 17 lines, and the Monitoring “Why” column plus the grip-strength target to single lines each (e.g. “Distinguishes training-related inflammation from chronic background inflammation” → “Separates training from chronic inflammation”). Also tightened
action_1_sub,action_3_sub, andmonitoring_cadence, cutting rendered body text from 6,591 to 5,983 characters and roughly 240 pt of layout height.
Issues 01/09/2026 06:00
- 2.6 / 2.9 — At-A-Glance opens with an imperative: [at_a_glance] begins “Exercise against an external load.” (QRS line 434), a bare imperative that addresses the reader; the ER states it declaratively at line 501 (“Resistance training is exercise against an external load”).
Fixes 01/09/2026 06:00
- 2.6 / 2.9 — At-A-Glance imperative removed: [at_a_glance] now opens “Resistance training is exercise against an external load.” instead of the bare imperative “Exercise against an external load.”, restoring the ER’s declarative phrasing (ER line 501). Word count stays within the 60-word limit at 59.